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Abstract Gastrin (G17) and N-carboxymethylgastrin (G17-
Gly) have been shown to stimulate the growth of colon cancer
cells both in vivo and in vitro. The identity of the receptor me-
diating these e¡ects is controversial. A recent study demon-
strated the presence of a low a⁄nity binding site for G17 and
G17-Gly on the DLD-1 human colon cancer cell line. The goal
of the current study was to further investigate the role of this
receptor in mediating the growth-promoting e¡ects of gastrin
peptides. Binding of [Leu15]G17 and [Leu15]G17-Gly to DLD-1
cell membranes in competition with [3H]G17-Gly was exam-
ined. Binding of [3H]cholecystokinin-8 (CCK8) to DLD-1 cell
membranes was also assessed. Whole cell binding experiments
were carried out using [125I-Tyr12,Leu15]G17-Gly. In addition,
the ability of [Leu15]G17 and [Leu15]G17-Gly to stimulate cell
growth, as determined by cell counting, was tested. [Leu15]G17
and [Leu15]G17-Gly competed with [3H]G17-Gly at both a high
and a low a⁄nity site on DLD-1 membranes. The IC50 values
for [Leu15]G17 were 6.0U1038 M and 6.9U1036 M while those
for [Leu15]G17-Gly were 3.2U1039 M and 4.9U1036 M.
[3H]CCK8 did not bind to either site. [Leu15]G17-Gly also com-
peted with [125I-Tyr12,Leu15]G17-Gly at both a high and a low
a⁄nity site on DLD-1 cells with similar a⁄nities as observed
with membranes. [Leu15]G17 and [Leu15]G17-Gly signi¢cantly
stimulated the growth of DLD-1 cells in a dose-dependent and
biphasic manner. The binding pro¢les of the peptides tested
suggest that these sites are di¡erent from previously identi¢ed
wild-type and mutant CCK1 or CCK2 receptors.
8 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
Key words: Gastrin; Glycine-extended gastrin; Colon cancer;
Cell growth; Receptor binding
1. Introduction
Receptors belonging to the cholecystokinin (CCK) family
are known to mediate the biological e¡ects of gastrin and
cholecystokinin. To date, two such receptors (CCK1 and
CCK2) have been identi¢ed and cloned [1,2]. The receptors
are commonly distinguished by their selectivity for gastrin 17
(G17) and CCK8. CCK8 binds both the CCK1 and CCK2
receptors with high a⁄nity while gastrin is selective for the
CCK2 receptor. In addition to binding G17 and CCK8, the
CCK2 receptor also interacts with gastrin fragments and pro-
cessing intermediates as well as a variety of non-peptide an-
tagonists. The human CCK2 receptor has been pharmacolog-
ically characterized and shown to have the following rank
order of a⁄nities for its ligands: CCK8sG17s pentagas-
trinsL-365,260sCCK4sN-carboxymethylgastrin (G17-
Gly) [3,4]. The highest a⁄nity ligands bind with sub-nano-
molar a⁄nity while the lowest (G17-Gly) binds with micro-
molar a⁄nity. In addition to the wild-type receptor, mutant
CCK2 receptors which are the result of alternative splicing or
point mutations have also been discovered [5^8]. These recep-
tors bind CCK2 receptor ligands with similar a⁄nities and the
same rank order as the wild-type receptor. The role and dis-
tribution of these variant receptors have yet to be clari¢ed.
The observation that G17 is a potent growth factor for
gastrointestinal mucosa has led to investigations of a role
for this hormone in the growth of gastrointestinal cancers.
Studies have indicated a possible role in the growth of gastric
carcinomas [9^11] but the e¡ect on colon cancer is more con-
troversial. Early studies demonstrated a mitogenic e¡ect of
G17 on both normal and cancerous colonic epithelia [12^
14]. The normal adult colon, however, does not express
CCK2 receptors [15]. This is also the case for the majority
of colon cancer specimens [16^18]. In addition, colon cancer
patients do not show increased serum levels of G17 [19^21]
and there appears to be no correlation between a hypergas-
trinemic state and disease [22,23].
It has been shown that colon cancer cells secrete intermedi-
ates of progastrin processing but not the mature, amidated
peptide [24,25]. G17 and G17-Gly are separately derived
from G34-Gly in normal gastric G cells and are found at
comparable concentrations in the circulation [26,27]. Numer-
ous studies have shown that G17-Gly stimulates the growth of
colon cancer cells in vitro and in vivo [28^31]. The results of
these studies suggest that the e¡ect of G17-Gly is mediated by
a receptor di¡erent from the wild-type CCK1 or CCK2 recep-
tors. However, reports di¡er as to the a⁄nity and selectivity
of such a receptor. A recent study demonstrated the presence
of a micromolar a⁄nity receptor for G17-Gly on the DLD-1
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human colon cancer cell line [32]. The current study was
undertaken to further characterize the receptor for G17-Gly
on DLD-1 cells using optimized conditions.
2. Materials and methods
2.1. Cells and reagents
DLD-1 and CHO-K1 cells were purchased from the American Type
Culture Collection (Manassas, VA, USA). DLD-1 cells were cultured
in RPMI 1640 containing 10% fetal calf serum while CHO-K1 cells
were grown in F12-K medium containing 10% fetal calf serum. Cells
were grown at 37‡C in an atmosphere of 5% CO2 and maintained at
sub-con£uent levels. N-K-9-Fluorenylmethyloxycarbonyl (Fmoc) ami-
no acids and O-(benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexa-
£uorophosphate (HBTU), 1-hydroxybenzotriazole (HOBt), piperi-
dine, and N,N-diisopropylethylamine (DIEA) for the ACT 90
peptide synthesizer were purchased from Advanced ChemTech
(Louisville, KY, USA). Rink Amide Am resin and Fmoc-Gly-Wang
resin were purchased from NovaBiochem (San Diego, CA, USA).
Fmoc-amide resin with Knorr linker and peptide synthesis grade di-
methylsulfoxide, N,N-dimethylformamide (DMF), tetrahydrofuran,
HBTU, HOBt, DIEA and piperidine for the ABI 432A peptide syn-
thesizer were purchased from Applied Biosystems/Perkin-Elmer (Fos-
ter City, CA, USA). Diethylether, NH4OH, MgCl2, Tris^HCl, tri-
£uoroacetic acid (TFA), DIEA, and peptide synthesis grade
dichloromethane (DCM) and DMF for the ACT90 peptide synthesiz-
er were from Fisher Scienti¢c (Rockford, IL, USA). Ethanedithiol,
thioanisole, HEPES, EGTA, and trypan blue were from Sigma Al-
drich (Milwaukee, WI, USA). [3H]Propionyl-CCK8 ([3H]CCK8; spe-
ci¢c activity of 60 Ci/mmol) was purchased from Amersham Life
Sciences (Elk Grove, IL, USA).
2.2. Peptide synthesis
Peptides were synthesized using Fmoc chemistry at either a 0.025
mM scale on an ABI 432A peptide synthesizer (Applied Biosystems/
Perkin-Elmer) as reported previously [33] or at a 0.5 mM scale on an
ACT 90 peptide synthesizer (Advanced ChemTech). With the ACT 90
peptide synthesizer, G17 and CCK8 were synthesized on Rink Amide
Am resin while G17-Gly was synthesized on Gly-Wang resin. The
reactive side chains of tyrosine, aspartic acid, and glutamic acid
were t-but protected. Fmoc removal was accomplished using 20%
piperidine in DMF and monitored at 290 nm. Couplings were carried
out with a four-fold excess of amino acids using in situ activation with
HBTU in 30% DCM/DMF. Coupling times were 40 min and com-
pletion was monitored using the Kaiser test [34]. Deprotection times
were 20 min up to residue 10 and 35 min for the remainder of the
synthesis. Peptides were cleaved from the resin using TFA/thioanisole/
EDT/H2O (36:2:1:1, v/v) for 15 min at 0‡C followed by 105 min at
room temperature.
2.3. Peptide puri¢cation and characterization
Peptides were analyzed and puri¢ed on a dual pump Gilson high
performance liquid chromatograph (HPLC). Solvent A was 50 mM
NH4HCO3 and solvent B was 60% CH3CN in 50 mM NH4HCO3.
Analytical HPLC was carried out on either a Vydac 218TP54 column
(C18, 5 Wm particle size, 4.6 mmU250 mm) or a Phenomenex 00G-
4252-Y0 column (spherical C18, 5 Wm particle size, 3 mmU250 mm) at
£ow rates of 1 ml/min or 0.5 ml/min, respectively. For preparative
HPLC, either a preparative Vydac 218TP1022 column (C18, 5 Wm
particle size, 22 mmU250 mm) with a £ow rate of 9 ml/min or a
Phenomenex semi-preparative 00G-4252-NO column (spherical C18,
5 Wm particle size, 10 mmU250 mm) column with a £ow rate of
4 ml/min was used. Peptides were obtained at s 95% purity. Molec-
ular weights of peptides were veri¢ed using electrospray ionization
mass spectrometry on a Perkin-Elmer quadrupole mass spectrometer.
2.4. Radiolabeled peptides
Custom iodination of [Leu15]G17-Gly and subsequent HPLC puri-
¢cation was carried out by Peninsula Laboratories using the chlor-
amine T method (Peninsula Laboratories, San Carlos, CA, USA). The
speci¢c activity of the 125I-peptide was 1582 Ci/mmol. For the tritiated
peptide, [3P,5P-I-Tyr12,Leu15]G17-Gly was synthesized at a 0.025 mM
scale on an ABI 432A peptide synthesizer using N-K-Fmoc amino
acids. Tritiation of the precursor peptide was carried out using cata-
lytic dehalogenation as previously published [35]. The speci¢c activity
of the resulting labeled peptide was 25 Ci/mmol.
2.5. Radioligand binding
Experiments using [3P,5P-3H-Tyr12,Leu15]G17-Gly ([3H]G17-Gly)
were performed with membrane fractions prepared from low passage
cells (29^33). Membrane preparations (240 Wg/ml protein concentra-
tion) were incubated in 10 mM HEPES containing 1 mM EGTA, 130
mM NaCl, and 5 mM MgCl2 for 60 min at 27‡C with 50 nM
[3H]G17-Gly and concentrations of [Leu15]G17-Gly or [Leu15]G17
from 10312 M to 1034 M. The low speci¢c activity of the tritiated
peptide did not allow discrimination of both sites at lower radioligand
concentration. Therefore, binding of [Leu15]G17-Gly, to receptors on
whole cells, was also assessed in competition with a low concentration
of [125I-Tyr12,Leu15]G17-Gly. DLD-1 cells (2U106 cells/well) were in-
cubated in 100 mM Tris (pH 7.4) for 60 min at 27‡C with 50 pM [125I-
Tyr12,Leu15]G17-Gly and concentrations of [Leu15]G17-Gly from
10312 M to 1034 M and displacement of [125I-Tyr12,Leu15]G17-Gly
from whole cells by CCK8 was also tested. The ¢nal reaction volume
for all experiments was 250 Wl. Non-speci¢c binding was determined
in the presence of 1034 M [Leu15]G17-Gly. The reaction was termi-
nated by rapid ¢ltration through Whatman GF/C glass ¢ber ¢lters
that had been presoaked at 4‡C in incubation bu¡er containing 0.1%
bovine serum albumin. Filtration was carried out on a Brandell cell
harvester (Biomedical RpD Laboratories, Gaithersburg, MD, USA).
Filters were washed three times with ice-cold 50 mM Tris^HCl bu¡er,
pH 7.4. Filters were air-dried and then soaked in Ultima Gold MV
scintillation cocktail and the bound radioactivity was measured with a
1209 Rackbeta liquid scintillation counter (Wallac, Gaithersburg,
MD, USA). Binding of [3H]CCK8 to DLD-1 cell membranes and
CHO-K1 cell membranes expressing human CCK2 receptors was
also tested at concentrations of 0.1 and 50 nM as previously reported
[33].
2.6. Cell growth studies
Before beginning growth experiments, the stability of the test pep-
tides in the presence of cells was determined using HPLC. This was
done by incubating 20 000 cells/well in 24-well plates with serum free
medium containing 1035 M [Leu15]G17-Gly or 1035 M [Leu15]G17.
Samples of media were removed at 24-h intervals for HPLC analysis.
The presence of mycoplasma in cells was examined using the Myco-
plasma Detection Kit from American Type Culture Collection.
Growth studies were performed using either 48- or 96-well plates.
Low passage cells (29^33) were harvested at 70^90% con£uence and
used for growth studies. Cells were seeded in 48-well plates at a den-
sity of 7000 cells/well or in 96-well plates at a density of 3000 cells/well
in serum-containing medium and allowed to attach for 48 h. The
medium was removed and replaced with serum-free medium. Various
concentrations of test peptide were added to the inner 24 wells of 48-
well plates or inner 60 wells of 96-well plates. Cells were allowed to
grow for an additional 72 h and the medium was removed. Cells were
detached using 0.05% trypsin and 0.02% EDTA and counted with the
aid of a hemocytometer under an inverted light microscope.
2.7. Statistical analysis
All data were analyzed using Graphpad Prizm software (Graphpad
Software, San Diego, CA, USA). Comparison of ¢t for one- and two-
site binding was determined using the F-test. Statistical signi¢cance of
growth data was assessed using the one-way analysis of variance.
3. Results
3.1. Binding of G17 and G17-Gly to DLD-1 cells and
membranes
Both [125I-Tyr12,Leu15]G17-Gly and [3H]G17-Gly bound in
a saturable and displaceable manner to DLD-1 cells and
membrane preparations, respectively. Total binding repre-
sented less than 1% of the total added radioligand in all ex-
periments and speci¢c binding was 60^70% of total binding.
Both [Leu15]G17-Gly and [Leu15]G17 were able to displace
the [3H]G17-Gly from DLD-1 membranes in a dose-depen-
dent manner (Fig. 1). Non-linear regression analysis of the
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results ¢t the data for binding of both peptides to a two-site
model with a high level of signi¢cance (P6 0.0001). The IC50
values for binding to the two sites were 3.2U1039 M and
4.9U1036 M for [Leu15]G17-Gly and 6.0U1038 M and
6.9U1036 M for [Leu15]G17. The fractional abundance of
the two sites was in good accord with high a⁄nity binding
comprising 20S 5% and 26S 12% of the total bound radio-
activity for [Leu15]G17-Gly and [Leu15]G17, respectively.
Competition of [Leu15]G17-Gly with [125I-Tyr12,Leu15]G17-
Gly for receptors on whole cells also showed two sites
(P6 0.01) with IC50 values of 0.83U1039 M and 8.2U1036
M. High a⁄nity binding comprised 18S 5% of the total
bound radioactivity. [3H]CCK8 was unable to bind to
DLD-1 cell membranes at concentrations of 0.1 nM and 50
nM and CCK8 was unable to displace [125I-Tyr12,Leu15]G17-
Gly from DLD-1 cells at concentrations as high as 1034 M.
By contrast, [3H]CCK8 bound in a saturable and displaceable
manner to CHO-K1 cells expressing human CCK2 receptors
(data not shown).
3.2. Mitogenic e¡ects of G17 and G17-Gly on DLD-1 cells
Both [Leu15]G17-Gly and [Leu15]G17 were shown to be
stable in the presence of DLD-1 cells for a period of 72 h
at 37‡C with no appreciable decrease in HPLC peak size (data
not shown). [Leu15]G17-Gly and [Leu15]G17 stimulated cell
growth in a dose-dependent and biphasic manner with max-
imal stimulation at 1039 M and 1038 M, respectively (Fig. 2).
4. Discussion
Our results show that a heterogeneous population of recep-
tors for both G17 and G17-Gly is present on DLD-1 cells.
The presence of these sites in similar proportions on both
whole cells and membrane preparations suggests that their
numbers are not regulated by the presence of guanine nucleo-
tides as is the case for high and low a⁄nity states of G pro-
tein-coupled receptors. The inability of [3H]CCK8 to bind to
either site suggests that these are di¡erent from both wild-type
and mutant CCK1 and CCK2 receptors identi¢ed to date. The
higher a⁄nity of G17-Gly than of G17 at both sites also
supports this conclusion. The ability of the G17 and G17-
Gly to stimulate growth of DLD-1 cells at low concentrations
(6 1038 M) suggests that it is the high a⁄nity site that medi-
ates the mitogenic e¡ects of these peptides.
The identity of the receptor which mediates the trophic
e¡ects of G17 and G17-Gly on both normal and cancerous
colonic cells is controversial. Some groups have demonstrated
the presence of nanomolar a⁄nity sites on various primary
and cultured tissues [36^38] while others have detected sites
with micromolar a⁄nity [32,39]. The selectivity of these sites
for G17 and G17-Gly is also in dispute. Stepan et al. showed
the presence of a nanomolar a⁄nity receptor on HT-29 cells
by saturation studies using 125I-G(2^17)-Gly up 0.5 nM [36].
Mauss et al. demonstrated the presence of a similar site on
HT-29 cells using 125I-G17 [37]. In addition, saturation experi-
ments with 0.01^0.5 nM 125I-G17 showed the presence of high
a⁄nity sites for gastrin on 57% of 67 primary colon cancer
specimens [38]. In contrast, Yang et al. found a micromolar
a⁄nity site for both G17 and G17-Gly on DLD-1 cells by
competition experiments with 125I-G17-Gly and G17-Gly
[32]. Imdahl et al. showed the presence of a similar, micro-
molar a⁄nity gastrin binding site on 36% of 102 primary co-
lorectal cells by competition experiments with 125I-G17 and
G17 [39].
Assuming that both binding sites exist, it is not surprising
that the various studies above could detect only a single site.
The groups reporting only nanomolar binding sites for G17
and G17-Gly relied on saturation experiments with low con-
centrations of 125I-labeled peptides. The conditions used in
each of these studies would be insu⁄cient to detect the pres-
ence of micromolar sites since the Kd of such a site would be
considerably higher than the highest radioligand concentra-
tion used. Thus, a normal saturation assay using 125I-labeled
peptides would be unable to detect the presence of a hetero-
geneous population of receptors with nanomolar and micro-
molar a⁄nities since the radioligand would ultimately saturate
only the high a⁄nity sites. By contrast, the reports in which
only micromolar a⁄nity sites were detected were based on
competition experiments with a small range (1039^1034 M)
and number (5) of unlabeled ligand concentrations. Our early
Fig. 1. Binding of [Leu15]G17 (E) and [Leu15]G17-Gly (R) to DLD-
1 membranes. [Leu15]G17 results are the average of two experiments
with four replicates each. [Leu15]G17-Gly results are the average of
¢ve experiments with three to six replicates for each concentration.
Results are presented as meanSS.D. P6 0.0001 for two-site binding
¢t.
Fig. 2. Stimulation of growth of DLD-1 cells by [Leu15]G17 (white
bars) and [Leu15]G17-Gly (gray bars). Results are meanSS.D. and
represent six experiments with four to ¢ve replicates each for
[Leu15]G17-Gly and four experiments with four to ¢ve replicates
each for [Leu15]G17. *P6 0.05, **P6 0.01.
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radioligand binding experiments with both the DLD-1 and
HT-29 cell lines demonstrated the presence of a single, micro-
molar a⁄nity site similar to that shown by Yang et al. [32].
These experiments used [3H]G17-Gly with the same number
and range of ligand concentrations used by Yang et al. Such
conditions would not be adequate to detect the presence of a
high a⁄nity site since cold ligand concentrations spanning at
least two orders of magnitude on either side of the IC50
should be used. Further optimization of conditions, including
the use of a larger number and range of cold ligand con-
centrations from 10312 M to 1034 M G17 or G17-Gly, al-
lowed us to detect a second, high a⁄nity site on DLD-1 cells.
Further experiments are currently being performed using HT-
29 cells.
Studies by Ishizuka et al. on the mitogenic e¡ects of neuro-
tensin on pancreatic cancer cells demonstrated a similar bi-
phasic growth response to that observed here [40]. The group
showed dose-dependent phospholipase C activation in re-
sponse to neurotensin. In addition, they also observed
cAMP activation but only at high peptide concentrations.
They proposed that both high and low a⁄nity receptors me-
diate the biphasic growth response. Growth experiments car-
ried out by Stepan et al. [36] and Mauss et al. [37] with HT-29
cells showed a similar biphasic growth response to G17 and
G17-Gly to that shown here with DLD-1 cells. It is possible
that, in colon cancer cells, high a⁄nity receptors mediate a
G17- or G17-Gly-induced stimulation of growth and activa-
tion of low a⁄nity receptors results in decreased proliferation.
Further investigation of the secondary messenger responses in
these cells is required.
The results presented here may help to clarify some of the
current controversy surrounding the binding a⁄nity of the so-
called glycine-extended gastrin receptor. These results together
with the discovery of multiple a⁄nity states for other recep-
tors including the CCK1 and CCK2 receptors [41,42] empha-
size the importance of using appropriate radioligands and
conditions that allow detection of high and low a⁄nity recep-
tors at both ends of the a⁄nity spectrum. Further studies
using other colon cancer cell lines and primary tissue cultures
are warranted to investigate the possibility of heterogeneous
receptor populations for G17 and G17-Gly.
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